Macleods Combination Blood Pressure Tablets Recalled in 3,744 Bottles Classified as Class II: Two Lots Expiring May 31, 2027, Initiated by the Company on October 7 and Classified by the FDA on October 26
Washington — According to media reporting of Food and Drug Administration recall information, Macleods Pharma USA is recalling 3,744 bottles of olmesartan medoxomil, amlodipine and hydrochlorothiazide combination tablets, and the FDA has classified the action as a Class II recall.
The affected product includes 3,528 bottles of 30 tablets, lot 12251163A, National Drug Code 33342-246-07, and 216 bottles of 90 tablets, lot 12251163B, National Drug Code 33342-246-10. Both lots expire on May 31, 2027.
The company initiated the voluntary recall on October 7, the FDA classified it on October 26, and the bottles were distributed nationwide in the United States.
The reporting states the recall is limited to the two identified lots and does not apply to every bottle of this combination drug or to other blood pressure medications. This report relays only the product and lot facts in the recall information, without individual medication advice, and checking should rely on the FDA recall record and bottle packaging.
Published by GSM · USA (original Chinese edition)
Photo: 食品药品监督固定图库（GSM asset-packs）
CDC Updates Measles Data on November 6: 5,182 Confirmed Cases in 2026 as of November 5, With 43 New Outbreaks and 96 Percent of Cases Outbreak Associated2026-11-10
Bechtel Medical Wound VOX Receives FDA 510(k) Clearance: The First Cleared System Combining Negative Pressure and Topical Oxygen Therapy, With a Limited Release in December2026-11-10